AD
Andrew Dodson
UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ-Hybridisation (UK NEQAS ICC & ISH)
United Kingdom
Authors
- AR
Anthony Rhodes
Institute of Biomedical Sciences
United Kingdom
- BJ
Bharat Jasani
School of Medicine, Cardiff University
United Kingdom
- DC
Dong Chan Moon
Division of Antimicrobial Resistance Research, National Institute of Health, Korea Disease Control and Prevention Agency
Republic of Korea
- DW
Dong Woo Shin
Department of Laboratory Medicine, Seoul National University Bundang Hospital
Republic of Korea
- GL
George L. Kumar
Discovery Life Sciences Services GmbH (Formerly Targos Molecular Pathology GmbH)
Germany
- GB
Gudrun Bänfer
Department Biomarker Academy, Discovery Life Sciences Services GmbH (Formerly Targos Molecular Pathology GmbH)
Germany
- HK
Hyunji Kim
Department of Laboratory Medicine, Seoul National University Bundang Hospital
Republic of Korea
- KU
Kyoung Un Park
Department of Laboratory Medicine, Seoul National University Bundang Hospital
Republic of Korea
- LK
Lam Kieu Mong Thy
Department of Pathology, Tu Du Hospital
Vietnam
- NT
Ngo Thi Minh Hanh
Department of Pathology, 108 Military Central Hospital
Vietnam
- NV
Nguyen Van Tin
Bureau of Accreditation Vietnam, Center for Standardization and Quality Control in Medical Laboratory of Ho Chi Minh City (CSQL)
Vietnam
- RM
Rachel Marrington
Birmingham Quality (Member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust
United Kingdom
- RD
Rolf Diezko
Department Biomarker Academy, Discovery Life Sciences Services GmbH (Formerly Targos Molecular Pathology GmbH)
Germany
- SP
Suzanne Parry
UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ-Hybridisation (UK NEQAS ICC & ISH)
United Kingdom
